CN101611046A - 抗病毒的核苷类似物 - Google Patents

抗病毒的核苷类似物 Download PDF

Info

Publication number
CN101611046A
CN101611046A CNA2008800038586A CN200880003858A CN101611046A CN 101611046 A CN101611046 A CN 101611046A CN A2008800038586 A CNA2008800038586 A CN A2008800038586A CN 200880003858 A CN200880003858 A CN 200880003858A CN 101611046 A CN101611046 A CN 101611046A
Authority
CN
China
Prior art keywords
alkyl
substituted
aryl
compound
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2008800038586A
Other languages
English (en)
Chinese (zh)
Inventor
Y·S·巴布
P·钱德
V·S·库马
P·L·科蒂安
吴明万
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biocryst Pharmaceuticals Inc
Original Assignee
Biocryst Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharmaceuticals Inc filed Critical Biocryst Pharmaceuticals Inc
Publication of CN101611046A publication Critical patent/CN101611046A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNA2008800038586A 2007-01-12 2008-01-11 抗病毒的核苷类似物 Pending CN101611046A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88027807P 2007-01-12 2007-01-12
US60/880,278 2007-01-12

Publications (1)

Publication Number Publication Date
CN101611046A true CN101611046A (zh) 2009-12-23

Family

ID=39471795

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2008800038586A Pending CN101611046A (zh) 2007-01-12 2008-01-11 抗病毒的核苷类似物

Country Status (19)

Country Link
US (1) US8440813B2 (enExample)
EP (2) EP2535345A1 (enExample)
JP (1) JP2010515760A (enExample)
CN (1) CN101611046A (enExample)
AU (1) AU2008206406A1 (enExample)
CA (1) CA2674589A1 (enExample)
CY (1) CY1113282T1 (enExample)
DK (1) DK2114980T3 (enExample)
ES (1) ES2390188T3 (enExample)
HR (1) HRP20120758T1 (enExample)
IL (1) IL199664A0 (enExample)
MX (1) MX2009007333A (enExample)
NZ (2) NZ598927A (enExample)
PH (1) PH12012502284A1 (enExample)
PL (1) PL2114980T3 (enExample)
PT (1) PT2114980E (enExample)
SG (1) SG177974A1 (enExample)
SI (1) SI2114980T1 (enExample)
WO (1) WO2008089105A2 (enExample)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102015714A (zh) * 2008-04-23 2011-04-13 吉里德科学公司 用于抗病毒治疗的1’-取代的carba-核苷类似物
CN103052631A (zh) * 2010-07-22 2013-04-17 吉里德科学公司 用于治疗副黏病毒科病毒感染的方法和化合物
US9090642B2 (en) 2010-07-19 2015-07-28 Gilead Sciences, Inc. Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
CN104876935A (zh) * 2015-05-18 2015-09-02 南方医科大学 2-氨基吡咯并[1,2-f][1,2,4]三嗪类化合物、合成方法及应用
US9724360B2 (en) 2014-10-29 2017-08-08 Gilead Sciences, Inc. Methods for treating Filoviridae virus infections
CN107056775A (zh) * 2017-05-24 2017-08-18 佛山科学技术学院 丙型肝炎病毒ns5b聚合酶抑制剂
CN109071467A (zh) * 2016-03-09 2018-12-21 艾丽奥斯生物制药有限公司 无环抗病毒药
US10251904B2 (en) 2015-09-16 2019-04-09 Gilead Sciences, Inc. Methods for treating arenaviridae and coronaviridae virus infections
US10675296B2 (en) 2017-07-11 2020-06-09 Gilead Sciences, Inc. Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
US10836787B2 (en) 2017-05-01 2020-11-17 Gilead Sciences, Inc. Crystalline forms of (S)-2-ethylbutyl 2-(((S)-(((2R,3S,4R,5R)-5- (4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
US10988498B2 (en) 2009-09-21 2021-04-27 Gilead Sciences, Inc. Processes and intermediates for the preparation of 1′-substituted carba-nucleoside analogs
CN113214262A (zh) * 2020-02-05 2021-08-06 华创合成制药股份有限公司 一种含有胍基的化合物及其制备方法和用途
CN114190092A (zh) * 2020-07-14 2022-03-15 四川大学 3-去氧-2-酮糖酸含氮衍生物及其制备方法和用途

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124759B2 (en) 2007-05-09 2012-02-28 Abbott Laboratories Inhibitors of protein kinases
WO2008141079A1 (en) * 2007-05-10 2008-11-20 Biocryst Pharmaceuticals, Inc. Tetrahydrofuro [3 4-d] dioxolane compounds for use in the treatment of viral infections and cancer
TW200942243A (en) * 2008-03-05 2009-10-16 Biocryst Pharm Inc Antiviral therapeutic agents
US20090247750A1 (en) * 2008-03-28 2009-10-01 Biocryst Pharmaceuticals, Inc. Process for preparing nucleoside analogs
EP2313102A2 (en) 2008-07-03 2011-04-27 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
PE20161067A1 (es) 2009-02-10 2016-10-23 Gilead Sciences Inc Analogos carba-nucleosidicos para tratamiento antiviral
US7973013B2 (en) 2009-09-21 2011-07-05 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
US8455451B2 (en) 2009-09-21 2013-06-04 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
BR122021021135B1 (pt) * 2009-09-21 2022-08-30 Gilead Sciences, Inc Compostos análogos de 2-flúor substituído carba-nucleosídeo, composição farmacêutica e uso dos compostos análogos de 2´-flúoro substituído carbonucleosídeo
CN102918045A (zh) 2010-03-31 2013-02-06 百时美施贵宝公司 作为蛋白激酶抑制剂的取代的吡咯并三嗪
TW201201815A (en) 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
TW201305185A (zh) * 2010-09-13 2013-02-01 Gilead Sciences Inc 用於抗病毒治療之２’－氟取代之碳－核苷類似物
WO2012039791A1 (en) 2010-09-20 2012-03-29 Gilead Sciences, Inc. 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment
AU2011305652B2 (en) 2010-09-22 2016-10-20 Janssen Biopharma, Inc. Azido nucleosides and nucleotide analogs
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
WO2012142523A2 (en) 2011-04-13 2012-10-18 Gilead Sciences, Inc. 1'-substituted pyrimidine n-nucleoside analogs for antiviral treatment
SG195100A1 (en) 2011-07-01 2013-12-30 Bayer Ip Gmbh Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors
AR088441A1 (es) 2011-09-12 2014-06-11 Idenix Pharmaceuticals Inc Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales
CA2752008A1 (en) 2011-09-13 2013-03-13 Universite De Montreal Combination therapy using ribavirin as elf4e inhibitor
SG10201610936RA (en) 2011-12-22 2017-02-27 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
AU2013232378B2 (en) 2012-03-13 2017-09-28 Gilead Sciences, Inc. 2'- substituted carba-nucleoside analogs for antiviral treatment
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
AR090699A1 (es) 2012-04-18 2014-12-03 Biocryst Pharm Inc Compuestos inhibidores de la actividad de la arn polimerasa viral
US9611267B2 (en) 2012-06-13 2017-04-04 Incyte Holdings Corporation Substituted tricyclic compounds as FGFR inhibitors
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
AU2013344422A1 (en) * 2012-11-16 2015-07-02 Biocryst Pharmaceuticals, Inc. Antiviral azasugar-containing nucleosides
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
TWI649318B (zh) 2013-04-19 2019-02-01 英塞特控股公司 作為ｆｇｆｒ抑制劑之雙環雜環
AU2014331863C1 (en) 2013-10-11 2019-05-16 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
UA119050C2 (uk) * 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
WO2015143712A1 (en) 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
TWI678369B (zh) 2014-07-28 2019-12-01 美商基利科學股份有限公司 用於治療呼吸道合胞病毒感染之噻吩並［３,２-ｄ］嘧啶、呋喃並［３,２-ｄ］嘧啶及吡咯並［３,２-ｄ］嘧啶化合物類
TWI673283B (zh) 2014-08-21 2019-10-01 美商基利科學股份有限公司 ２’－氯胺基嘧啶酮及嘧啶二酮核苷類
ES2749679T3 (es) 2014-10-22 2020-03-23 Bristol Myers Squibb Co Compuestos de pirrolotriazina amina sustituidos como inhibidores de PI3k
WO2016064957A1 (en) 2014-10-22 2016-04-28 Bristol-Myers Squibb Company Bicyclic heteroaryl amine compounds as pi3k inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
AU2016219822B2 (en) 2015-02-20 2020-07-09 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
GEAP202215528A (en) 2015-03-06 2022-11-10 Atea Pharmaceuticals Inc B-D-2'-DEOXY-2'a-FLUORO-2'-B-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
KR102185996B1 (ko) 2015-09-23 2020-12-02 머크 샤프 앤드 돔 코포레이션 4'-치환된 뉴클레오시드 리버스 트랜스크립타제 억제제 및 그의 제조법
JP2019507759A (ja) 2016-03-09 2019-03-22 ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー− ユーシーエルエー メディカル センター 外陰部膣カンジダ症の予防及び治療で使用するための方法及びキット
AU2017241524B2 (en) 2016-03-28 2021-07-08 Incyte Corporation Pyrrolotriazine compounds as TAM inhibitors
LU100724B1 (en) 2016-07-14 2018-07-31 Atea Pharmaceuticals Inc Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
BR112019004297A2 (pt) 2016-09-07 2019-05-28 Atea Pharmaceuticals Inc método, uso de uma quantidade eficaz de um composto, composto, e, composição farmacêutica.
WO2018089306A1 (en) * 2016-11-10 2018-05-17 Oyagen, Inc. Methods of treating and inhibiting ebola virus infection
SG11201906163TA (en) 2017-02-01 2019-08-27 Atea Pharmaceuticals Inc Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
CN110869028B (zh) 2017-03-14 2023-01-20 吉利德科学公司 治疗猫冠状病毒感染的方法
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
US11040975B2 (en) 2017-12-08 2021-06-22 Merck Sharp & Dohme Corp. Carbocyclic nucleoside reverse transcriptase inhibitors
EP3773753A4 (en) 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS
TW201946630A (zh) 2018-05-04 2019-12-16 美商英塞特公司 Fgfr抑制劑之鹽
ES2991427T3 (es) 2018-05-04 2024-12-03 Incyte Corp Formas sólidas de un inhibidor de FGFR y procedimientos para preparar las mismas
MX2021006993A (es) 2018-12-12 2021-10-22 Janssen Biopharma Inc Analogos de nucleosidos de ciclopentilo como antivirales.
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
GEAP202415945A (en) 2019-10-14 2024-04-25 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
AU2020395185A1 (en) 2019-12-04 2022-06-02 Incyte Corporation Derivatives of an FGFR inhibitor
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CN118662520A (zh) 2020-01-27 2024-09-20 吉利德科学公司 用于治疗SARS CoV-2感染的方法
WO2021158248A1 (en) 2020-02-04 2021-08-12 Oyagen, Inc. Method for treating coronavirus infections
EP4106876B1 (en) 2020-02-18 2025-09-17 Gilead Sciences, Inc. Antiviral compounds
TWI884403B (zh) 2020-02-18 2025-05-21 美商基利科學股份有限公司 抗病毒化合物
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
TWI874791B (zh) 2020-02-18 2025-03-01 美商基利科學股份有限公司 抗病毒化合物
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
US11613553B2 (en) 2020-03-12 2023-03-28 Gilead Sciences, Inc. Methods of preparing 1′-cyano nucleosides
EP4132651B1 (en) 2020-04-06 2026-03-18 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
ES3041698T3 (en) 2020-05-29 2025-11-13 Gilead Sciences Inc Remdesivir for the treatment of viral infections
EP4172160A2 (en) 2020-06-24 2023-05-03 Gilead Sciences, Inc. 1'-cyano nucleoside analogs and uses thereof
HUE067491T2 (hu) 2020-08-27 2024-10-28 Gilead Sciences Inc Vegyületek és eljárások vírusfertõzések kezelésére
EP4323405A1 (en) 2021-04-12 2024-02-21 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
KR102923359B1 (ko) 2021-04-16 2026-02-05 길리애드 사이언시즈, 인코포레이티드 아미드를 사용한 카르바뉴클레오시드를 제조하는 방법
AR126101A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
JP2024525164A (ja) 2021-06-17 2024-07-10 アテア ファーマシューティカルズ， インコーポレイテッド 有利な抗ｈｃｖ併用療法
EP4387977A1 (en) 2021-08-18 2024-06-26 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
IL310854A (en) 2021-08-20 2024-04-01 Shionogi & Co Nucleoside compounds and their drug derivatives possessing viral growth inhibitory activity
AU2023227794A1 (en) 2022-03-02 2024-10-17 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6472393B1 (en) 1999-01-13 2002-10-29 Genentech, Inc. Serine protease inhibitors
JP5230052B2 (ja) * 2000-05-26 2013-07-10 イデニクス（ケイマン）リミテツド フラビウイルスおよびペスチウイルス治療のための方法および組成物
EP1572705A2 (en) * 2002-01-17 2005-09-14 Ribapharm, Inc. Sugar modified nucleosides as viral replication inhibitors
CA2523083C (en) 2003-04-25 2014-07-08 Gilead Sciences, Inc. Antiviral phosphonate analogs
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
KR20070100237A (ko) 2004-10-29 2007-10-10 바이오크리스트 파마수티컬즈, 인코퍼레이티드 치료용 푸로피리미딘 및 티에노피리미딘
TW200942243A (en) * 2008-03-05 2009-10-16 Biocryst Pharm Inc Antiviral therapeutic agents
EP2313102A2 (en) * 2008-07-03 2011-04-27 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46762E1 (en) 2008-04-23 2018-03-27 Gilead Sciences, Inc 1′-substituted carba-nucleoside analogs for antiviral treatment
US8853171B2 (en) 2008-04-23 2014-10-07 Gilead Sciences, Inc. 1′-substituted carba-nucleoside analogs for antiviral treatment
CN102015714A (zh) * 2008-04-23 2011-04-13 吉里德科学公司 用于抗病毒治疗的1’-取代的carba-核苷类似物
US10988498B2 (en) 2009-09-21 2021-04-27 Gilead Sciences, Inc. Processes and intermediates for the preparation of 1′-substituted carba-nucleoside analogs
US9090642B2 (en) 2010-07-19 2015-07-28 Gilead Sciences, Inc. Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
CN103052631A (zh) * 2010-07-22 2013-04-17 吉里德科学公司 用于治疗副黏病毒科病毒感染的方法和化合物
US10696679B2 (en) 2010-07-22 2020-06-30 Gilead Sciences, Inc. Methods and compounds for treating paramyxoviridae virus infections
CN103052631B (zh) * 2010-07-22 2015-11-25 吉里德科学公司 用于治疗副黏病毒科病毒感染的方法和化合物
US10065958B2 (en) 2010-07-22 2018-09-04 Gilead Sciences, Inc. Methods and compounds for treating Paramyxoviridae virus infections
US11344565B2 (en) 2014-10-29 2022-05-31 Gilead Sciences, Inc. Methods for the preparation of ribosides
US9949994B2 (en) 2014-10-29 2018-04-24 Gilead Sciences, Inc. Methods for treating Filoviridae virus infections
CN107073005A (zh) * 2014-10-29 2017-08-18 吉利德科学公司 治疗丝状病毒科病毒感染的方法
US9724360B2 (en) 2014-10-29 2017-08-08 Gilead Sciences, Inc. Methods for treating Filoviridae virus infections
US10251898B2 (en) 2014-10-29 2019-04-09 Gilead Sciences, Inc. Methods for treating Filoviridae virus infections
CN107073005B (zh) * 2014-10-29 2021-12-24 吉利德科学公司 治疗丝状病毒科病毒感染的方法
US10695357B2 (en) 2014-10-29 2020-06-30 Gilead Sciences, Inc. Methods for treating filoviridae virus infections
CN104876935A (zh) * 2015-05-18 2015-09-02 南方医科大学 2-氨基吡咯并[1,2-f][1,2,4]三嗪类化合物、合成方法及应用
US10251904B2 (en) 2015-09-16 2019-04-09 Gilead Sciences, Inc. Methods for treating arenaviridae and coronaviridae virus infections
CN109071467A (zh) * 2016-03-09 2018-12-21 艾丽奥斯生物制药有限公司 无环抗病毒药
US11472826B2 (en) 2016-03-09 2022-10-18 Janssen Pharmaceutica Nv Acyclic antivirals
CN109071467B (zh) * 2016-03-09 2023-04-04 艾丽奥斯生物制药有限公司 无环抗病毒药
US10836787B2 (en) 2017-05-01 2020-11-17 Gilead Sciences, Inc. Crystalline forms of (S)-2-ethylbutyl 2-(((S)-(((2R,3S,4R,5R)-5- (4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
CN107056775A (zh) * 2017-05-24 2017-08-18 佛山科学技术学院 丙型肝炎病毒ns5b聚合酶抑制剂
US10675296B2 (en) 2017-07-11 2020-06-09 Gilead Sciences, Inc. Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
CN113214262A (zh) * 2020-02-05 2021-08-06 华创合成制药股份有限公司 一种含有胍基的化合物及其制备方法和用途
CN114190092A (zh) * 2020-07-14 2022-03-15 四川大学 3-去氧-2-酮糖酸含氮衍生物及其制备方法和用途

Also Published As

Publication number Publication date
US8440813B2 (en) 2013-05-14
WO2008089105A2 (en) 2008-07-24
NZ598927A (en) 2013-09-27
MX2009007333A (es) 2009-08-31
ES2390188T3 (es) 2012-11-07
EP2114980B1 (en) 2012-06-27
SG177974A1 (en) 2012-02-28
EP2535345A1 (en) 2012-12-19
DK2114980T3 (da) 2012-09-24
JP2010515760A (ja) 2010-05-13
CY1113282T1 (el) 2016-04-13
PL2114980T3 (pl) 2012-11-30
AU2008206406A1 (en) 2008-07-24
US20100015094A1 (en) 2010-01-21
PT2114980E (pt) 2012-09-25
WO2008089105A3 (en) 2008-09-12
PH12012502284A1 (en) 2015-10-12
IL199664A0 (en) 2010-04-15
HK1138286A1 (en) 2010-08-20
SI2114980T1 (sl) 2012-11-30
HRP20120758T1 (hr) 2012-10-31
NZ578556A (en) 2012-04-27
EP2114980A2 (en) 2009-11-11
CA2674589A1 (en) 2008-07-24

Similar Documents

Publication Publication Date Title
CN101611046A (zh) 抗病毒的核苷类似物
US7429571B2 (en) Therapeutic furopyrimidines and thienopyrimidines
US8163703B2 (en) Hepatitis C therapies
US7994139B2 (en) Antiviral therapeutic agents
AU2008251555A1 (en) Tetrahydrofuro [3 4-D] dioxolane compounds for use in the treatment of viral infections and cancer
AU2012201345A1 (en) Hepatitis C therapies
HK1138286B (en) Antiviral nucleoside analogs
AU2012268918A1 (en) Antiviral nucleoside analogs

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20091223